SMAD9 (also known as SMAD8, MADH6, and Mothers against decapentaplegic homolog 9) is a homolog protein encoded by the SMAD9 gene. SMADs are a protein family that transduce receptors of the transforming growth factor beta (TGF-B) superfamily and are significant in regulating cell development. The name derives from two homologies: the "small" worm phenotype or Caenorhabditis elegans SMA and MAD family or "Mothers Against Decapentaplegic" of genes in the fruit fly Drosophila. SMAD9 is a critical "messenger" protein that translates extracellular signals into expression. The significance lies in how it dictates cell fate – signaling for synthesis/ growth, differentiation, or death – specifically within cardiovascular and skeletal systems.
Nomenclature and Classification SMAD9 is also known as or referred to as Smad8/9, Smad8A, Smad8B, MADH9, MADH6, and PPH2. Within the overall SMAD group, there are three sub-types of the protein that consist of R-Smads (receptor-regulated), I-Smads (inhibitory), and Co-SMADs (common partner). R-Smads, which include Smad1, Smad2, Smad3, Smad5, and Smad 8/9 are integral in signaling for the TGF-B receptor. I-Smads include Smad6 and Smad7 which work to suppress the activity of R-Smads by binding to the TGF-B receptors, blocking them from reaching the receptor to get activated. Without the action of I-Smads, the TGF-B and BMP signaling pathways would remain perpetually active. Before the name SMAD was created, the MAD (Mothers Against Decapentaplegic) genes were discovered in Drosophila (fruit flies). During Drosophila research, it was found that a mutation in the gene, MAD, in the mother, repressed the gene, decapentaplegic, in the embryo. The phrase "Mothers against" was added since mothers often form organizations opposing various issues e.g. Mothers Against Drunk Driving or (MADD); and based on a tradition of such unusual naming within the gene research community. Subsequent discovery of the human version of this gene was named MADH and SMAD9 became cataloged as MADH6 or MADH9. The many aliases of SMAD9 are a result of conflict between species. In early TGF-B research, a gene was found in Xenopus (frogs) and dubbed Smad8. Simultaneously, other scientists found a similar gene in humans and called it SMAD8. Later analysis of these genes revealed that the human version was not a direct ortholog of the frog Smad8. To differentiate the two genomic classes and clear up confusion, the human gene name was altered to be SMAD9. The most up-to-date version of this name as distinguished by the scientific community is SMAD9 but the MADH versions still linger in publishing and papers as are synonymous. Additionally, SMAD8 is still the most common term used in dated literature.
Structure To understand the specific structure of SMAD9, it is crucial to grasp the overall organization of general SMAD proteins. SMADs are approximately 400 to 500 amino acids in length consisting of two globular regions at the amino and carboxy termini connected by a linker region, a short amino acid sequence that connects functional domains within a single protein maintaining structure and flexibility. This linker region plays an important role in protein function and regulation, specifically for R-Smads. The two regions are highly conserved in R-Smads with the MH1 at the N-terminus, involved in DNA binding and MH2 at the C-terminus, which is responsible for interaction with other Smads and the recognition of transcriptional co-activators and co-repressors. R-Smads interact with DNA motifs on their N-terminus including the CAGAC and CAGCC variants. Receptor-phosphorylated R-Smads have the capability of forming heterotrimers via MH2 exchanges and these are believed to be effectors of TGF-B transcriptional regulation. R-Smads are phosphorylated in the nucleus at the linker domain by CDK8 and CDK 9 which alter the interaction of Smads with activators and repressors. Once an R-Smad is phosphorylated, the linker domain undergoes another phosphorylation modulation by GSK3 which labels Smads for their recognition by ubiquitin ligases and targets them for proteasome-mediated degradation after they carry out their role as transcription factors. The structure of SMAD9 allows it to function as both a DNA binder and a protein-docking station. Breaking down the R-Smad morphological components more specifically, the MH1 domain (N-terminus) contains two key regions for DNA binding and nuclear localization. This region has a hairpin structure that allows it to bind to BMP-response elements (BREs) which are specific DNA sequences that mediate transcriptional responses to BMP signaling. Furthermore, this terminal holds the Nuclear Localization Signal (NLS) which allows SMAD9 to enter the nucleus once activated. The MH2 domain (C-terminus) has three key constituents that prepare SMAD9 for interaction and activation to help unzip DNA and start the transcription process. The SSXS motif plays a key role in post-translational regulation of R-Smads. This motif is phosphorylated by Type I TGF-B and BMP receptors which initiates a conformational change that promotes R-Smad binding to Smad4 (the co-SMAD) via oligomerization, moving SMAD9 into the nucleus to regulate gene transcription.
… excerpt ends here. Continue reading the full article.
